# US 2003/0212103 A1 · Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, 2,3,- dihydroxybutanedioate salts and method of production

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0212103 A1
- Document ID: US20030212103A1
- Status: Published application
- Kind: A1
- Application number: 10/441,567
- Filed: 2003-05-20
- Published: 2003-11-13
- Earliest claimed: 2000-12-19
- Assignees: Pfizer Inc.
- Inventors: Joseph P. Lyssikatos; Derek L. Tickner; Linda S. Newton; Zheng J. Li; Clifford N. Meltz
- Web page: https://patentgrep.com/patent/US20030212103A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, 2,3-dihydroxy butanedioate salts having the formula shown below: 1 and to pharmaceutical compositions containing the above compound, methods of treating hyperproliferative diseases, such as cancers, in mammals, especially humans by administering the above compound, and to methods of preparing the crystal forms of the above compound and related compounds.

## Claims

### Claim 1

A crystal form of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, 2,3-dihydroxy butanedioate anhydrous salt.

### Claim 2 (depends on 1)

The crystal form according to claim 1, comprising high-intensity diffraction peaks at diffraction angles (2θ) of about 3.6, 17.2, 17.6, 18.8, 19.2, 20.4 and 22.1 in the powder X-ray diffraction analysis.

### Claim 3 (depends on 2)

The crystal form according to claim 2, comprising a powder X-ray diffraction pattern having characteristic peaks expressed in degrees (2θ) at approximately:
3 Angle Angle Angle 2 theta 2 theta 2 theta 3.6 16.9 23.4 6.2 17.2 25.1 7.2 17.6 25.5 9.5 18.8 26.0 10.8 19.2 26.7 12.3 19.7 27.6 12.5 20.4 28.2 13.8 21.7 28.5 14.5 22.1 29.0 16.0 22.6 29.9

### Claim 4 (depends on 3)

The crystal form according to claim 3, wherein said salt has a powder X-ray diffraction pattern substantially the same as the powder X-ray diffraction pattern shown in Graph 1.

### Claim 5 (depends on 1)

The crystal form according to claim 1, wherein said anhydrous salt is (+)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, 2,3-dihydroxy butanedioate.

### Claim 6 (depends on 1)

The crystal form according to claim 1, wherein said anhydrous salt is 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)- i-methyl-1H-quinolin-2-one, (−)-2,3-dihydroxy butanedioate.

### Claim 7 (depends on 5)

The crystal form according to claim 5, wherein said anhydrous salt is (+)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, (−)-2,3-dihydroxy butanedioate

### Claim 8 (depends on 1)

The crystal form according to claim 1, wherein said anhydrous salt is (−)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, 2,3-dihydroxy butanedioate.

### Claim 9 (depends on 1)

The crystal form according to claim 1, wherein said anhydrous salt is 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, (+)-2,3-dihydroxy butanedioate.

### Claim 10 (depends on 9)

The crystal form according to claim 9, wherein said anhydrous salt is (−)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, (+)-2,3-dihydroxy butanedioate.

### Claim 11 (depends on 1)

The crystal form according to claim 1, wherein said anhydrous salt has a melting point of 189° C.

### Claim 12

A crystal form of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, 2,3-dihydroxy butanedioate hydrate salt.

### Claim 13 (depends on 12)

The crystal form according to claim 12, comprising high-intensity diffraction peaks at diffraction angles (2θ) of about 5.1, 8.1, 18.2, 18.8, 20.2, 20.8, 23.6, 25.8 and 26.0 in the powder X-ray diffraction analysis.

### Claim 14 (depends on 13)

The crystal form according to claim 13, comprising a powder X-ray diffraction pattern having characteristic peaks expressed in degrees (2θ) at approximately:
4 Angle Angle Angle 2-theta 2-theta 2-theta 5.1 19.9 26.0 8.1 20.2 26.7 12.7 20.8 27.6 13.9 21.4 28.1 14.6 21.7 28.7 15.2 22.8 30.2 15.3 23.6 31.2 16.4 24.1 32.1 16.8 24.4 33.1 18.2 24.8 34.4 18.8 25.5 36.8 19.3 25.8 37.4

### Claim 15 (depends on 14)

The crystal form according to claim 14, wherein said crystal form has a powder X-ray diffraction pattern substantially the same as the powder X-ray diffraction pattern shown in Graph 2.

### Claim 16 (depends on 12)

The crystal form according to claim 12, wherein said hydrate is (+)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-12-methyl-1H-quinolin-2-one, 2,3-dihydroxy butanedioate.

### Claim 17 (depends on 12)

The crystal form according to claim 12, wherein said hydrate is 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, (−)-2,3-dihydroxy butanedioate.

### Claim 18 (depends on 17)

The crystal form according to claim 17, wherein said hydrate is (+)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, (−)-2,3-dihydroxy butanedioate

### Claim 19 (depends on 12)

The crystal form according to claim 12, wherein said hydrate is (−)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, 2,3-dihydroxy butanedioate.

### Claim 20 (depends on 12)

The crystal form according to claim 12, wherein said hydrate is 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, (+)-2,3-dihydroxy butanedioate.

### Claim 21 (depends on 20)

The crystal form according to claim 20, wherein said hydrate is (−)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, (+)-2,3-dihydroxy butanedioate

### Claim 22

A process for preparing a salt having the formula
5
comprising treating 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one with tartaric acid which provides high-intensity diffraction peaks at diffraction angles (2θ) of 5.1, 8.1, 18.2, 18.8, 20.2, 20.8, 23.6, 25.8 and 26.0 in the powder X-ray diffraction pattern.

### Claim 23 (depends on 22)

The process of claim 22, wherein said process is carried out in a mixture of THF and water.

### Claim 24 (depends on 22)

The process of claim 22, wherein said salt is (+)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, (−)-2,3-dihydroxy butanedioate hydrate salt.

### Claim 25 (depends on 22)

The process of claim 22, wherein said salt is (−)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, (+)-2,3-dihydroxy butanedioate hydrate salt.

### Claim 26

A process for preparing 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, 2,3-dihydroxy butanedioate anhydrous salt comprising azeotropic removal of water from 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, 2,3-dihydroxy butanedioate hydrate salt.

### Claim 27 (depends on 26)

The process of claim 26, wherein said anhydrous salt is (+)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, (−)-2,3-dihydroxy butanedioate anhydrous salt.

### Claim 28 (depends on 26)

The process of claim 26, wherein said anhydrous salt is (−)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, (+)-2,3-dihydroxy butanedioate anhydrous salt.

### Claim 29

A process for preparing a salt having the formula
6
comprising treating 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one with tartaric acid in a polar solvent at an elevated temperature to form an anhydrous crystal form which provides high-intensity diffraction peaks at diffraction angles (2θ) of about 3.6, 17.2, 17.6, 18.8, 19.2, 20.4 and 22.1 in the powder X-ray diffraction pattern.

### Claim 30 (depends on 29)

The process of claim 29, wherein said salt is (+)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-i H-quinolin-2-one, (−)-2,3-dihydroxy butanedioate anhydrous salt.

### Claim 31 (depends on 29)

The process of claim 29, wherein said salt is (−)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, (+)-2,3-dihydroxy butanedioate anhydrous salt.

### Claim 32 (depends on 29)

The process of claim 29, wherein the polar solvent is ethyl acetate.

### Claim 33 (depends on 1)

A method of treating a hyperproliferative disorder in a mammal which comprises administering to the mammal a therapeutically effective amount of a compound according to claim 1.

### Claim 34 (depends on 33)

The method of claim 33, wherein the method is for the treatment of a cancer selected from brain, squamous cell, bladder, gastric, pancreatic, breast, head, neck, oesophageal, prostate, colorectal, lung, renal, kidney, ovarian, gynecological and thyroid cancer.

### Claim 35 (depends on 1)

A method for the treatment of a hyperproliferative disorder in a mammal which comprises administering to the mammal a therapeutically effective amount of a polymorph according to claim 1 in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, and anti-androgens.

### Claim 36 (depends on 1)

A pharmaceutical composition comprising an amount of a compound according to claim 1 effective to treat a hyperproliferative disorder in a mammal, and a pharmaceutically acceptable carrier.

### Claim 37 (depends on 36)

The pharmaceutical composition of claim 36, wherein the hyperproliferative disorder is a cancer selected from brain, lung, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, oesophageal, gynecological and thyroid cancer.

### Claim 38 (depends on 36)

The pharmaceutical composition of claim 36, wherein the composition is adapted for oral administration.

### Claim 39 (depends on 38)

The pharmaceutical composition of claim 38, wherein the pharmaceutical composition is in the form of a tablet.

### Claim 40

A pharmaceutical composition comprising a therapeutically effective amount of a compound of clam 1 and a pharmaceutically acceptable carrier.
